GSK Looks To Capitalize On AstraZeneca’s Anemia Drug Knock-Back
Safety Profile Will Be Battleground
Executive Summary
AstraZeneca and FibroGen hit another safety roadblock with roxadustat, while GSK is hoping it might catch up with its rivals in the US.
You may also be interested in...
GSK’s Shingrix On Recovery Track In Q3 After Pandemic Slump
The shingles vaccine’s move to health care practices, as well as inventory moves, contributed to its 41% sales growth during the quarter after a difficult year due to COVID-19.
European Approval For Roxadustat Is Silver Lining For FibroGen
The EU approval is good news for FibroGen and marketing partner Astellas, but was expected, and still leaves it pondering its future after FDA knock-back.
Restructuring On The Table For FibroGen After Roxadustat Rejection
As anticipated, the FDA issued a complete response letter for roxadustat. While the drug is expected to win EU approval, it is unclear if FibroGen and AstraZeneca will be willing to fund another trial.